Plain-English translation of NCT03720470 on ClinicalTrials.gov ↗ · Source last updated · How we translate trials
Read our Atopic dermatitis research guide →Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This trial investigated whether a new daily oral medication called PF-04965842 could help adults with moderate to severe atopic dermatitis (a chronic skin condition causing intense itching and inflammation). Researchers compared this medication at two different doses against an existing injectable treatment and placebo, while all participants also used moisturizers and medicated creams as background therapy. The study was designed to measure how well the treatment reduced itching and improved skin symptoms over 20 weeks.
Many people with severe atopic dermatitis do not get adequate relief from topical creams and moisturizers alone, and current treatment options may require frequent injections or have other limitations. This trial was designed to see whether an oral medication could offer a more convenient and effective option for these patients.
Participants received either the new oral medication (at one of two doses), an existing injectable treatment, or placebo—all combined with standard moisturizers and topical medicated creams. Some participants received oral pills plus placebo injections every two weeks, while others received injections plus oral placebo. The trial lasted 20 weeks total, with the main treatment period running 16 weeks followed by 4 additional weeks. Participants who completed the study had the opportunity to enroll in a longer-term follow-up study.
AI-generated summary from trial data · Aug 3, 2026 · Not medical advice
United States